Form 4 for KLRS Kalaris Therapeutics, Inc.
Accepted 2023-07-21 00:00:00 ET · period of report 2023-07-19 · accession 0001209191-23-043119 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-07-21 | 2023-07-19+ | KLRS | Sinha Vikas | See Remarks, Dir, 10% | S - Sale | $3.45 | -2,635 | 1.19M | -0.2% | -$9,079 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-07-20 | S | D | 1,437 | $3.35 | 1,184,217 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.26 to $3.47. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| 2 | Common | Common Stock | 2023-07-19 | S | D | 1,198 | $3.56 | 1,185,654 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.53 to $3.62. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |